MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Soleno Therapeutics, Inc.(NASDAQ: SLNO)*
Organization & Developments: Soleno
Parents
Soleno Therapeutics, Inc.(NASDAQ: SLNO)*
Children
*Develops medical diagnostics and therapeutics based on its proprietary technology for precision metering of gas flow
*The company’s lead product, Diazoxide Choline Controlled-Release (DCCR), is a potent ATP-sensitive potassium (KATP) channel activator. DCCR is being developed for the treatment of Prader-Willi syndrome (PWS), a rare genetic disorder characterized by hyperphagia (excessive hunger), obesity, and cognitive impairment.
2018: Soleno Therapeutics Announces Joint Venture Agreement For Development And Commercialization Of CoSense Monitoring Technology
2018: Soleno Therapeutics Receives Fast Track Designation from FDA for DCCR for Treatment of Prader-Willi Syndrome_www.nasdaq.com
2018: Soleno Therapeutics: Rare Disease Pick With Significant Potential And Low Valuation_seekingalpha.com
2019: An In-Depth Look At Soleno Therapeutics_seekingalpha.com
2020: A Second Look At Soleno Therapeutics
2022: Soleno Therapeutics, Inc. (NASDAQ: SLNO) presented clinical data of diazoxide choline extended-release (DCCR) to treat Prader-Willi syndrome (PWS) from a Phase 3 trial and reported statistically significant changes in lean body mass, ratio of lean body mass to fat mass, levels of leptin, fasting insulin and adiponectin.
2023: Soleno Therapeutics: Impressive Data, But Never Forget Amarin_seekingalpha.com
2024: FDA delays approval decision until March on DCCR for excessive hunger in PWS
2024: Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families_ seekingalpha.com
2024: Soleno Therapeutics Jumps After FDA Says No Advisory Panel Meeting Needed for Prader-Willi Syndrome Drug
2024: Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments
2024: Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patient
2024: Soleno Therapeutics: PDUFA Extension May Be An Opportunity, But Not For Me_seekingalpha.com
2024: Soleno Therapeutics' SWOT analysis: DCCR approval could reshape PWS treatment landscape
2025: 5 FDA decisions to watch in the first quarter of 2025
2025: Soleno Therapeutics Announces U.S. FDA Approval of VYKAT(TM) XR to Treat Hyperphagia in Prader-Willi Syndrome
2025: Soleno Therapeutics: FDA Approval May Prove To Be A Pyrrhic Victory
2025: Soleno Therapeutics: Overbought On VYKAT Approval Enthusiasm
2026: Soleno Therapeutics’ Risky Bet on VYKAT XR: Commercial, Regulatory, and Funding Hurdles Threaten Path to Profitability
Jumps
*Key People: Soleno
Finance & Acquisitions: Soleno